Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 6/20 | 0.55 |
| ▸ | KDR | P35968 | 2/20 | 0.55 |
| ▸ | JAK3 | P52333 | 2/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | JAK1 | P23458 | 1/20 | 0.55 |
| ▸ | TYK2 | P29597 | 1/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 4/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.45 |
| ▸ | CLK2 | P49760 | 1/20 | 0.45 |
| ▸ | CDK7 | P50613 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5494272 | 0.86 | LCK (0.58) | LCKKDRJAK3MAPK14DYRK1A | |
| SCHEMBL27957917 | 0.85 | KDR (0.49) | LCKKDRJAK3MAPK14JAK2 | |
| SCHEMBL12575968 | 0.85 | SRC (0.61) | LCKKDRJAK3MAPK14ESR2 | |
| SCHEMBL2741576 | 0.84 | LCK (0.65) | LCKKDRJAK3MAPK14ADORA2A | |
| SCHEMBL3025007 | 0.83 | LCK (0.55) | LCKKDRJAK3MAPK14ADORA2A | |
| Benzene SCHEMBL27889171 | 0.82 | LCK (0.50) | LCKKDRJAK3MAPK14JAK2 | |
| SCHEMBL41115 | 0.81 | LCK (0.53) | LCKKDRJAK3MAPK14JAK2 | |
| SCHEMBL5488838 | 0.78 | MAP4K4 (0.61) | LCKKDRJAK3MAPK14MAP4K4 | |
| SCHEMBL25750391 | 0.76 | BRAF (0.63) | LCKKDRJAK3MAPK14 | |
| SCHEMBL24335889 | 0.76 | PIK3CA (0.55) | LCKKDRJAK3MAPK14DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359349-B2 | Substituted quinazolines as kinase inhibitors | INTELLIKINE LLC (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359349-B2 | Substituted quinazolines as kinase inhibitors | INTELLIKINE LLC (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150141442-A1 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| US-20150141442-A1 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| US-20140350248-A1 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | Intellikine, LLC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140350248-A1 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | Intellikine, LLC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20110160232-A1 | CERTAIN CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | INTELLIKINE LLC | 2011-06-30 | — | — | US | disclosed |
| US-20110160232-A1 | CERTAIN CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | INTELLIKINE LLC | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350248-A1 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | PIK3CA, PIK3CB, PIK3C3 | LCK 174/4885KDR 1523/4885JAK3 88/4885 |
| US-20150141442-A1 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | PIK3CA, PIK3CB, PIK3C3 | LCK 174/4885KDR 1523/4885JAK3 88/4885 |
| US-20110160232-A1 | CERTAIN CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | PIK3CA, PIK3C3, PRKACA | LCK 135/4885KDR 1244/4885JAK3 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.